Literature DB >> 19750576

Expression of thymidylate synthase and glutathione-s-transferase pi in patients with esophageal squamous cell carcinoma.

Jun-Xing Huang1, Feng-Yue Li, Wei Xiao, Zheng-Xiang Song, Rong-Yu Qian, Ping Chen, Eeva Salminen.   

Abstract

AIM: To investigate the expression of thymidylate synthase (TS) and glutathione-s-transferase pi (GST-pi) in esophageal squamous cell carcinoma and their association with the clinicopathologic characteristics.
METHODS: Immunohistochemical methods were used to detect the expression of TS and GST-pi in surgically resected formalin-fixed, paraffin-embedded esophageal squamous cell carcinoma (ESCC) tissue sections from 102 patients (median age, 58 years) and in 28 normal esophageal mucosa (NEM) samples. The relationship between TS and GST-pi expression and clinicopathologic factors was examined.
RESULTS: The expression of TS and GST-pi was not statistically significantly associated with age of the patients, tumor size, lymph node metastasis, depth of invasion or tumor stage. TS staining was positive in 17.86% of normal esophageal mucosa and in 42.16% of ESCC samples (P < 0.05). The expression level of TS was not only significantly lower in well-differentiated (21.88%) than in poorly-differentiated carcinomas (51.43%, P < 0.05), but was also significantly higher in samples from male patients (46.51%) than from female patients (18.75%, P < 0.05). GST-pi was positively stained in 78.57% of normal esophageal mucosa and in 53.92% of ESCC samples (P < 0.05). The expression level of GST-pi was also significantly higher in well-differentiated carcinomas (65.63%) than in poorly-differentiated carcinomas (35.00%, P < 0.05).
CONCLUSION: The expression of TS and of GST-pi may be used as molecular markers for the characterization of ESCC. Poorly-differentiated cells showed increased expression of TS and reduced expression of GST-pi.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19750576      PMCID: PMC2744189          DOI: 10.3748/wjg.15.4316

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients.

Authors:  Hidekazu Kuramochi; Koji Tanaka; Daniel Oh; Bethany J Lehman; Christy M Dunst; Dong Yun Yang; Steven R De Meester; Jeffery A Hagen; Kathleen D Danenberg; Tom R De Meester; Peter V Danenberg
Journal:  Int J Oncol       Date:  2008-01       Impact factor: 5.650

2.  Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

Authors:  H Bleiberg; T Conroy; B Paillot; A J Lacave; G Blijham; J H Jacob; L Bedenne; M Namer; P De Besi; F Gay; L Collette; T Sahmoud
Journal:  Eur J Cancer       Date:  1997-07       Impact factor: 9.162

3.  Association of GSTP1 polymorphism and survival for esophageal cancer.

Authors:  Jang-Ming Lee; Ming-Tsang Wu; Yung-Chie Lee; Shi-Yi Yang; Jin-Shing Chen; Hsao-Hsun Hsu; Pei-Ming Huang; Shuenn-Wen Kuo; Chun-Jean Lee; Chien-Jen Chen
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

4.  Relationship between proliferative activity of cancer cells and clinicopathological factors in patients with esophageal squamous cell carcinoma.

Authors:  Jun-Xing Huang; Wei Yan; Zheng-Xiang Song; Rong-Yu Qian; Ping Chen; Eeva Salminen; Jorma Toppari
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

5.  High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Authors:  Mary-Beth Moore Joshi; Yoshinori Shirota; Kathleen D Danenberg; Debbi H Conlon; Dennis S Salonga; James E Herndon; Peter V Danenberg; David H Harpole
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

6.  Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

Authors:  H-C Kwon; M S Roh; S Y Oh; S-H Kim; M C Kim; J-S Kim; H-J Kim
Journal:  Ann Oncol       Date:  2007-03       Impact factor: 32.976

7.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.

Authors:  H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

8.  Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.

Authors:  Takanori Miyoshi; Kazuya Kondo; Hiroaki Toba; Mitsuteru Yoshida; Haruhiko Fujino; Koichiro Kenzaki; Shoji Sakiyama; Masatsugu Takehisa; Akira Tangoku
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

9.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03

10.  Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Authors:  Sung-Hyun Kim; Hyuk-Chan Kwon; Sung Yong Oh; Dong Mee Lee; Suee Lee; Jong-Hoon Lee; Mee-Sook Roh; Dae-Cheol Kim; Ki-Jae Park; Hong-Jo Choi; Hyo-Jin Kim
Journal:  Am J Clin Oncol       Date:  2009-02       Impact factor: 2.339

View more
  9 in total

1.  Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma.

Authors:  Jun-Xing Huang; Wei Xiao; Wei-Chang Chen; Mao-Song Lin; Zheng-Xiang Song; Ping Chen; Yun-Lei Zhang; Feng-Yue Li; Rong-Yu Qian; Eeva Salminen
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 2.  Molecular mechanisms associated with chemoresistance in esophageal cancer.

Authors:  Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

3.  Decreased expression of GST pi is correlated with a poor prognosis in human esophageal squamous carcinoma.

Authors:  Zhihui Wang; Wei He; Guanrui Yang; Junsheng Wang; Zhong Wang; Jahn M Nesland; Ruth Holm; Zhenhe Suo
Journal:  BMC Cancer       Date:  2010-07-05       Impact factor: 4.430

4.  Glutathione s-transferases in pediatric cancer.

Authors:  Wen Luo; Michelle Kinsey; Joshua D Schiffman; Stephen L Lessnick
Journal:  Front Oncol       Date:  2011-10-24       Impact factor: 6.244

5.  Impact of alcohol dehydrogenase gene 4 polymorphisms on esophageal squamous cell carcinoma risk in a Chinese population.

Authors:  Xiaoling Xu; Jiwen Wang; Shuang-Mei Zhu; Ming Yang; Yun Fang; An Zhao; Qian Song; Weimin Mao
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 6.  Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments.

Authors:  Rao Khalid Mehmood
Journal:  Oncol Rev       Date:  2014-09-23

Review 7.  Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.

Authors:  Rao Khalid Mehmood; Jody Parker; Shakil Ahmed; Eyas Qasem; Ahmed A Mohammed; Muhammed Zeeshan; Ernest Jehangir
Journal:  World J Oncol       Date:  2014-06-25

8.  Inhibition of glutathione metabolism attenuates esophageal cancer progression.

Authors:  Liang Peng; Ruixia Linghu; Demeng Chen; Jing Yang; Xiaoxue Kou; Xiang-Zhen Wang; Yi Hu; Yi-Zhou Jiang; Junlan Yang
Journal:  Exp Mol Med       Date:  2017-04-21       Impact factor: 8.718

9.  A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma.

Authors:  A Mirza; M Brown; C McNulty; J Valentine; A Annesley; S Galloway; I Welch; C M West; S Pritchard
Journal:  Gastroenterol Res Pract       Date:  2013-03-03       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.